There are currently 52 active clinical trials seeking participants for NSCLC research studies. The states with the highest number of trials for NSCLC participants are California, New York, Texas and Florida.
Epidemiology of Young Lung Cancer - Survey
NCT04640259
Recruiting
This is a 100% virtual (remote), case-case study to explore potential environmental, lifestyle and genetic factors that may be associated with driver mutations of young lung cancer in the U.S.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: USC Keck School of Medicine, Los Angeles, California +1 locations
Conditions: NSCLC
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
Recruiting
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Mayo Clinc, Phoenix, Arizona +3 locations
Conditions: Advanced Solid Tumor, NSCLC, CRC
Register for Updates
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587
Recruiting
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Melanoma, Solid Tumor, NSCLC, HNSCC, Sarcoma, Squamous Cell Carcinoma
Register for Updates